美国 · SEC FORM 4
UroGen Pharma Ltd.
URGN · Nasdaq · CIK 0001668243 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
14 同一窗口内观察到的 Form 4 交易行
8 sales · 6 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2021-11-18 · Schoenberg Mark.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 7,766,918
- 上期报告
- 6,247,498
- 日均成交量
- 783,547
- 回补天数
- 9.9
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2021-11-18 | Schoenberg Mark | 买入 (P) | Ordinary Shares | 160 | USD 13.10 | USD 2,096 | SEC 申报 ↗ |
| 2021-05-17 | Smith Jason Drew | 买入 (P) | Common Stock | 2,500 | USD 15.71 | USD 39,275 | SEC 申报 ↗ |
| 2021-05-17 | Henderson Molly | 买入 (P) | Common Stock | 2,500 | USD 15.85 | USD 39,625 | SEC 申报 ↗ |
| 2020-12-14 | Barrett Elizabeth A. | 买入 (P) | Ordinary Shares | 10,000 | USD 18.50 | USD 185,000 | SEC 申报 ↗ |
Form 4 申报证据
32 transaction lines in the latest 365-day window; 216 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | Degnan Chris | 卖出 (S) | Ordinary Shares | 2,202 | USD 36.69 | USD 80,791 | SEC 申报 ↗ |
| 2026-10-08 | Degnan Chris | 期权行权/转换 (M) | Ordinary Shares | 4,483 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-08 | Smith Jason Drew | 卖出 (S) | Ordinary Shares | 1,519 | USD 42.54 | USD 64,618 | SEC 申报 ↗ |
展开近期 Form 4 证据 (24 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | Degnan Chris | 卖出 (S) | Ordinary Shares | 2,202 | USD 36.69 | USD 80,791 | SEC 申报 ↗ |
| 2026-10-08 | Degnan Chris | 期权行权/转换 (M) | Ordinary Shares | 4,483 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-08 | Smith Jason Drew | 卖出 (S) | Ordinary Shares | 1,519 | USD 42.54 | USD 64,618 | SEC 申报 ↗ |
| 2026-09-08 | Schoenberg Mark | 卖出 (S) | Ordinary Shares | 871 | USD 42.92 | USD 37,383 | SEC 申报 ↗ |
| 2026-09-07 | Smith Jason Drew | 期权行权/转换 (M) | Ordinary Shares | 3,334 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-07 | Schoenberg Mark | 期权行权/转换 (M) | Ordinary Shares | 1,667 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-26 | Robinson James A. Jr. | 期权行权/转换 (M) | ordinary shares | 2,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-20 | Schoenberg Mark | 卖出 (S) | ordinary shares | 60,677 | USD 47.05 | USD 2,854,853 | SEC 申报 ↗ |
| 2026-07-09 | Schoenberg Mark | 卖出 (S) | Ordinary Shares | 10,000 | USD 40.00 | USD 400,000 | SEC 申报 ↗ |
| 2026-06-22 | Schoenberg Mark | 卖出 (S) | Ordinary Shares | 10,000 | USD 35.01 | USD 350,100 | SEC 申报 ↗ |
| 2026-06-08 | Schoenberg Mark | 卖出 (S) | Ordinary Shares | 5,222 | USD 27.30 | USD 142,561 | SEC 申报 ↗ |
| 2026-06-08 | Schoenberg Mark | 期权行权/转换 (M) | Ordinary Shares | 10,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-26 | Robinson James A. Jr. | 期权行权/转换 (M) | ordinary shares | 2,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-08 | Schoenberg Mark | 卖出 (S) | Ordinary Shares | 10,000 | USD 30.00 | USD 300,000 | SEC 申报 ↗ |
| 2026-02-03 | Smith Jason Drew | 卖出 (S) | Ordinary Shares | 7,479 | USD 19.69 | USD 147,262 | SEC 申报 ↗ |
| 2026-02-03 | Schoenberg Mark | 卖出 (S) | Ordinary Shares | 7,373 | USD 19.69 | USD 145,174 | SEC 申报 ↗ |
| 2026-01-31 | Smith Jason Drew | 期权行权/转换 (M) | Ordinary Shares | 15,500 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-31 | Schoenberg Mark | 期权行权/转换 (M) | Ordinary Shares | 13,333 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-26 | Wildman Daniel George | 期权行权/转换 (M) | ordinary shares | 2,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-26 | WEN LEANA | 期权行权/转换 (M) | ordinary shares | 2,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-26 | Robinson James A. Jr. | 期权行权/转换 (M) | ordinary shares | 2,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-26 | Holden Stuart | 期权行权/转换 (M) | ordinary shares | 2,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-26 | BUTITTA CYNTHIA M | 期权行权/转换 (M) | ordinary shares | 2,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-19 | Schoenberg Mark | 卖出 (S) | Ordinary Shares | 10,000 | USD 25.00 | USD 250,000 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | URGN |
| CIK | 0001668243 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 216 transaction lines from 2020-01-03 to 2026-10-08 4 P purchase lines · 90 S sale lines · 122 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.